This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366:1759–69.
Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:57–73.
Larocca A, Dold SM, Zweegman S, Terpos E, Wäsch R, D’Agostino M, et al. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018;32:1697–712.
Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131:301–10.
Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110:3281–90.
Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817–25.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38.
Moreau P, Kolb B, Attal M, Caillot D, Benboubker L, Tiab M, et al. Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. Blood. 2015;125:3100–4.
Leleu X, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, et al. Carfilzomib weekly plus melphalan and prednisone in newly diagnosed elderly multiple myeloma (IFM 2012-03). Blood. 2015;25:4224–30.
Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019;133:1953–63.
Durie BGM, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.
Acknowledgements
The authors wish to thank the patients and families, the centers that participated to the study, the CRC teams in the centers and the IFM teams. The authors wish to thank the sponsor Lille academic hospital, the DRC: Dib Malek, Chanaz Louni, Axel Duquenoy, Angeline Dautremepuis; the biochemistry platform: Brigitte Onraed, Suzanna Schraen; Lille hospital central pharmacy: Sylvie Brice, Beatrice Thielemans; the statistical analysis platform: Alain Duhamel, François Machuron, Julien Labreuche, Maéva Kyheng; and the pharmacovigilance platform: Thavarak Ouk. A special thanks to Dr Claire Mathiot, the administrative director of IFM for decades and at the time of that study. The IFM wish to thank and honor Dr Brigitte Kolb who sadly passed away before the paper was published.
Funding
The study was supported by Amgen for funding and drug supply of carfilzomib.
Author information
Authors and Affiliations
Consortia
Contributions
Conception and design: XL, TF. Conduction of Trial: XL, TF, and MOP. Collection and assembly of data: AB, SG, CGM, VR, LK, BK, MT, CA, NM, JVM, PB, PL, AP, MR, AJ, KBM, MLC, JF, PR, AS, FO, LV, SC, FK, SR, OD, CHK, JF, OF, DRW, JCE, VD, EV, PM, HAL, CH, TF, and XL. Data analysis and interpretation: XL, AB, MK, and AD. Paper writing: XL, AB, and MK.
Corresponding author
Ethics declarations
Competing interests
XL honorarium from BMS Celgene, Janssen, Merck, Takeda, Amgen, Sanofi, Novartis, Roche, Karyopharm, Oncopeptide. LK honorarium from Janssen, Amgen, Celgene, advisory committees for Janssen, Amgen, Celgene, travel support from Janssen, Amgen. MR consultancy for Amgen, Celgene, Takeda. KBM consultancy and honorarium from Celgene, Janssen, Amgen, Takeda. OD honorarium from Celgene, Janssen, Takeda, Amgen. MA consultancy and research funding from Amgen, Celgene, Janssen, consultancy for Sanofi. PM honorarium and advisory committees for Amgen, Celgene, Janssen, Abbvie, Takeda, and speakers bureau for Amgen, Celgene, Janssen, Abbvie. HAL honorarium and advisory committees for Amgen, Celgene, Janssen, Sanofi, Abbvie, Takeda, research funding from Amgen, Celgene, Sanofi, Takeda. CH honorarium from Celgene, Janssen, Amgen, Takeda, research funding from Celgene, Janssen. TF honorarium and advisory committees and speakers bureau for Celgene, Janssen, Takeda, Amgen, Sanofi, Karyopharm, Oncopeptides.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Bobin, A., Kyheng, M., Guidez, S. et al. Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma. Leukemia 36, 881–884 (2022). https://doi.org/10.1038/s41375-021-01415-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-021-01415-x
